Anti-KDR Intrabody [Tat] (IAB-B066(T))
Recombinant anti-KDR intrabody in fusion with HIV Tat works within cells to block the transport of KDR, expressed in E. coli cells. It can inhibit VEGF induced signalling and affect the maturation of the receptor.
Specifications
- Immunogen
- human kinase insert domain receptor
- Host
- mouse
- Type
- scFv-Tat
- Cell Penetrating Peptide
- TAT
TAT was able to deliver different proteins, such as horseradish peroxidase and RNase A across cell membrane into the cytoplasm in different cell lines in vitro. The size range of proteins with effective delivery is from 30kDa to 120-150kDa. In one study, TAT-fused proteins are rapidly internalized by lipid raft−dependent macropinocytosis using a transducible TAT−Cre recombinase reporter assay on live cells. In another study, a TAT-fused protein was delivered into mitochondria of breast cancer cells and decreased the survival of breast cancer cells, which showed capability of TAT-fusion proteins to modulate mitochondrial function and cell survival. However, very few in vivo studies have succeeded. In one study, in vivo delivery of TAT- or penetratin-crosslinked Fab fragments yielded varied organ distributions and an overall increase in organ retention, which showed tissue localization.
- Species Reactivity
- human
- Applications
- Can be useful in applications such as: Immunofluorescence; Enzyme-linked Immunosorbent Assay; Functional studies
Target
- Alternative Names
- KDR; kinase insert domain receptor; FLK1; CD309; VEGFR; VEGFR2; vascular endothelial growth factor receptor 2; soluble VEGFR2
- Entrez Gene ID
- 3791
- UniProt ID
- A0A024RD88
For lab research use only, not for diagnostic, therapeutic or any in vivo human use.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: